Dr. Barth serves as the Director of Liver Transplantation and Associate Director of The University of Chicago Medicine Transplant Institute. His clinical practice focuses on kidney, pancreas, and liver transplant with specific accomplishments in living donor kidney and liver transplantation. Dr. Barth has pioneered minimally invasive surgery for living kidney donation and developed and has performed over 500 ‘scarless,’ single-port laparoscopic donor nephrectomies.
Dr. Barth has active clinical and basic research interests that include novel immunosuppressive therapies, immunologic tolerance, and the use of genetically engineered animal organs for human transplantation (xenotransplantation). Dr. Barth led an active lab investigating transplant tolerance and pre-clinical models of composite facial and limb transplantation, toward the clinical goal of reconstructive transplantation.
University of Wisconsin
- Transplant Surgery Fellowship
2006
Duke University
- General Surgery Residency
2004
Mass. General Hosp/Harvard Medical School
- Transplant Immunology Fellowship
2001
Duke University
MD - Medical Degree
1997
Evaluation of a Ureteral Stent Removal Protocol in Adult Kidney Transplant Recipients.
Evaluation of a Ureteral Stent Removal Protocol in Adult Kidney Transplant Recipients. Open Forum Infect Dis. 2024 Sep; 11(9):ofae510.
PMID: 39310271
The Seattle Heart Failure Model in Kidney Transplant Recipients.
The Seattle Heart Failure Model in Kidney Transplant Recipients. J Clin Med. 2023 Dec 11; 12(24).
PMID: 38137683
Impact of Renal Replacement Therapy on Rejection among Liver Transplant Recipients.
Impact of Renal Replacement Therapy on Rejection among Liver Transplant Recipients. Prog Transplant. 2023 Dec; 33(4):348-355.
PMID: 37981809
Comparing High- and Low-Model for End-Stage Liver Disease Living-Donor Liver Transplantation to Determine Clinical Efficacy: A Systematic Review and Meta-Analysis (CHALICE Study).
Comparing High- and Low-Model for End-Stage Liver Disease Living-Donor Liver Transplantation to Determine Clinical Efficacy: A Systematic Review and Meta-Analysis (CHALICE Study). J Clin Med. 2023 Sep 06; 12(18).
PMID: 37762738
The Accuracy of Nonstandardized MELD/PELD Score Exceptions in the Pediatric Liver Allocation System.
The Accuracy of Nonstandardized MELD/PELD Score Exceptions in the Pediatric Liver Allocation System. Transplantation. 2023 10 01; 107(10):e247-e256.
PMID: 37408100
Normothermic Machine Perfusion of Donor Livers for Transplantation in the United States: A Randomized Controlled Trial.
Normothermic Machine Perfusion of Donor Livers for Transplantation in the United States: A Randomized Controlled Trial. Ann Surg. 2023 Nov 01; 278(5):e912-e921.
PMID: 37389552
Peri-operative Reparixin therapy resulted in 50% 5-year insulin independence rate: The University of Chicago experience.
Peri-operative Reparixin therapy resulted in 50% 5-year insulin independence rate: The University of Chicago experience. Clin Transplant. 2023 05; 37(5):e14981.
PMID: 37013956
Digital imaging software versus the "eyeball" method in quantifying steatosis in a liver biopsy.
Digital imaging software versus the "eyeball" method in quantifying steatosis in a liver biopsy. Liver Transpl. 2023 03 01; 29(3):268-278.
PMID: 36651194
Which cava anastomotic techniques are optimal regarding immediate and short-term outcomes after liver transplantation: A systematic review of the literature and expert panel recommendations.
Which cava anastomotic techniques are optimal regarding immediate and short-term outcomes after liver transplantation: A systematic review of the literature and expert panel recommendations. Clin Transplant. 2022 Oct; 36(10):e14681.
PMID: 35567584
Impact of Steroid Only Induction on Rejection in Simultaneous Liver-Kidney Transplantation.
Impact of Steroid Only Induction on Rejection in Simultaneous Liver-Kidney Transplantation. Prog Transplant. 2022 12; 32(4):363-369.
PMID: 36062719